Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Notes Payables (2020 - 2024)

Aytu Biopharma has reported Notes Payables over the past 7 years, most recently at $4.0 million for Q4 2024.

  • Quarterly Notes Payables rose 291.03% to $4.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2024, up 291.03% year-over-year, with the annual reading at $2.4 million for FY2024, 53.23% up from the prior year.
  • Notes Payables was $4.0 million for Q4 2024 at Aytu Biopharma, down from $4.3 million in the prior quarter.
  • Over five years, Notes Payables peaked at $10.4 million in Q1 2023 and troughed at $41318.0 in Q4 2020.
  • The 4-year median for Notes Payables is $2.4 million (2024), against an average of $3.3 million.
  • Year-over-year, Notes Payables crashed 86.19% in 2023 and then soared 291.03% in 2024.
  • A 4-year view of Notes Payables shows it stood at $41318.0 in 2020, then soared by 17880.06% to $7.4 million in 2022, then plummeted by 86.19% to $1.0 million in 2023, then soared by 291.03% to $4.0 million in 2024.
  • Per Business Quant, the three most recent readings for AYTU's Notes Payables are $4.0 million (Q4 2024), $4.3 million (Q3 2024), and $2.4 million (Q2 2024).